LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M

Shots: LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) As per the deal, Tanabe Pharma will receive up to $435M in upfront & near-term milestone payments together with potential downstream milestones and tiered royalties on net sales Dersimelagon’s NDA for EPP & XLP was submitted to the FDA in Jun 2026 & remains under review, with no regulatory approval to date Ref: Businesswire   |  Image:  LEO Pharma & Tanabe  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post LEO Pharma to Acquire Global Rights to Tanabe Pharma’s Dersimelagon for ~$435M appeared first on PharmaShots.